Enterin
Latest round
- Series A
Last raised
- Jul 2017
Total raised
- $13M
Investors
- 1
About Enterin
Enterin Inc.Founded in 2016 and headquartered in Philadelphia, US, Enterin Inc. specializes in therapeutics for neurodegenerative diseases.Enterin Inc. specializes in the development of innovative therapeutics aimed at addressing neurodegenerative diseases, with a particular focus on Parkinson's disease. Their flagship product is a novel drug candidate designed to enhance the delivery of therapies to the central nervous system, thereby improving the efficacy of treatment outcomes for patients. Enterin's approach targets the underlying mechanisms of neurodegeneration, aiming to alleviate symptoms and potentially slow disease progression. The company’s products are currently in various stages of clinical development, with a target market that includes healthcare providers, research institutions, and pharmaceutical companies across North America and Europe.Enterin Inc. generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical entities, which may involve co-development agreements and licensing deals for their proprietary drug candidates. Transactions typically revolve around milestone payments tied to the achievement of specific clinical development phases, as well as potential royalties on future sales of marketed products. The company’s revenue model may include contractual agreements that stipulate shared responsibilities in research and development, reflecting a B2B transaction structure that emphasizes collaboration. plans to leverage these funds to support the further development of its innovative therapeutics. The company is looking to expand its product offerings with new drugs targeting Parkinson's disease, although specific release dates have not been disclosed. Additionally, Enterin aims to expand its market reach into Europe and Asia by 2025, seeking strategic partnerships that will facilitate entry into these regions.
Who invested in Enterin
1 investor across 1 round
See all investors in Enterin
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 10, 2017
Amount
$13M
Investors
Questions about Enterin
Who invested in Enterin?
Enterin has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Enterin raised?
Enterin has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Enterin last raise money?
Enterin's most recent round on record is a Series A, in Jul 2017.
What does Enterin do?
Enterin is a pharmaceuticals company.
Where is Enterin headquartered?
Enterin is headquartered in Philadelphia, US.
Which VCs invest in companies like Enterin?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Enterin's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Enterin? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.